# A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

> **NCT03418493** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 63 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** LY3316531 - IV
- **DRUG:** LY3316531 - SC
- **DRUG:** Placebo - IV

## Key facts

- **NCT ID:** NCT03418493
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-30
- **Primary completion:** 2018-12-24
- **Final completion:** 2019-07-29
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03418493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03418493, "A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03418493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*